Figure 3.
VnP-16 promotes osteogenic cell attachment through direct interaction with β1 integrin. (a) Attachment of human osteogenic cells pretreated with EDTA (5 mM), MnCl2 (500 μM), or heparin (100 μg/ml) to VnP-16. The cells were seeded onto plates that were precoated with VnP-16 (9.1 μg/cm2) for 1 h. (b) The effects of various integrin-blocking antibodies on cell attachment to VnP-16. (c–e) Immunoblotting (c) and densitometric analysis (d) of β1 integrin, and cell attachment to VnP-16 (e) in osteogenic cells that were transfected with a control (Con) or β1 integrin-specific siRNA (10 nM; β1 integrin). (f) Streptavidin-bead pulldown assay with the biotinylated SP or biotinylated VnP-16 peptides from extracts of osteogenic cells that were cultured on biotinylated SP- or biotinylated VnP-16-coated dishes for 30 min. Data in (a,b,e) (n=4), and (d) (n=2) represent the mean±SD. **P<0.01